Heqet Therapeutics announced it has received £6.6 million in its series A round of funding led by new investors Claris Ventures SGR SpA and 2Invest AG on March 23, 2022. As part of the transaction Pietro Puglisi of Claris Ventures SGR SpA, Heikki Lanckriet of 2Invest, will join the board of the company as directors. The company issued common stock in the transaction.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
9.4 EUR | -0.53% | +3.87% | +26.17% |
Apr. 24 | 2invest AG Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
Mar. 27 | Geopacific Resources Extends Maturity Date of Bearer Bonds | MT |
1st Jan change | Capi. | |
---|---|---|
+26.17% | 57.94M | |
+22.16% | 82.52B | |
+10.67% | 17.65B | |
+53.39% | 16.79B | |
+8.12% | 14.58B | |
-5.51% | 12.22B | |
+8.45% | 11.06B | |
-0.88% | 10.93B | |
+26.23% | 9.94B | |
-6.21% | 9.25B |
- Stock Market
- Equities
- 2INV Stock
- News 2invest AG
- Heqet Therapeutics S.R.L. announced that it has received £6.6 million in funding from Claris Ventures SGR SpA, 2invest AG